Oncogene panel testing
ONCOgenics analyzes genes associated with targeted therapies for treatment of cancer and genes involved in hereditary cancer
ONCOgenics Tumor detects alterations in tumor DNA related to personalized oncological therapies. ONCOgenics Germline analyzes all genes involved in hereditary cancer, from DNA obtained from the patient’s blood or saliva.
The highest score in the “Oncogene panel testing” for ONCOgenics
This service has participated in the external quality control program “Oncogene panel testing” (offered by EMQN) last 3 years. This program evaluates the ability of laboratories to analyze 3 samples and detect mutations in genes associated with cancer. Some of the mutations are present in only 2% of the cells analyzed (1% of the DNA molecules). Therefore, it measures sensitivity (correctly detection of genetic alterations) and specificity (determining the absence of mutations).
ONCOgenics correctly detected all mutations, obtaining 100% sensitivity and specificity in 2015, 2016 and 2017. The final rating awarded in the 3 calls was 2.00 / 2.00, much higher than the average of other participating centers.
This service has been developed by DREAMgenics and the IMOMA Molecular Medicine Laboratory.